hypercholesterolemia HIV Pravastatin Phytosterols Human immunodeficiency virus Lipid
Conditions
Interventions
Pravastatin 40 mg/day and 2 g/day of phytosterols enriched cereal beverage for 4 weeks,Pravastatin 40 mg/day for 4 weeks,2 g/day of phytosterols enriched cereal beverage for 4 weeks
Experimental Drug,Active Comparator Drug,Active Comparator Dietary Supplement
combination group,pravastatin monotherapy,phytosterol monotherapy
Sponsors
Faculty of Medicine, Prince of Songkla University
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) HIV patients aged 20 years or older whose LDL cholesterol was 130 mg/dL or higher at least 2 times in 3 months apart 2) the ARVs had not changed within the previous 6-months period
Exclusion criteria
Exclusion criteria: 1) had an active opportunistic infection 2) were taking any lipid lowering agents during 2-month period before enrollment 3) had hypersensitivity to any statins 4) had transaminase enzyme 3 times higher than the upper limit of normal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percent LDL-c reduction of combination therapy to monotherapy 4 weeks after each intervention phase enzymatic in vitro assay for direct quantitative using MODULAR P800 analyzer | — |
Secondary
| Measure | Time frame |
|---|---|
| percent changes of TC, TG, HDL-c and LDL-c after the first phase at 4 week after the first intervention phase enzymatic in vitro assay for direct quantitative using MODULAR P800 analyzer | — |
Countries
Thailand
Contacts
Public ContactNoppadol Kietsiriroje
faculty of medicine, Prince of Songkla University
Outcome results
None listed